Post hoc analysis of NAPOLI 3 in metastatic pancreatic cancer (770 patients, 217 aged ≥70): NALIRIFOX benefit versus gemcitabine plus nab-paclitaxel was preserved in older patients (median OS 10.0 months), with no sign of more toxicity; no statistical comparison done.
Secondary analysisn = 770 patients
Macarulla et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial